Intravenous Immunoglobulin Market is valued at USD 10.46 Billion in 2021 and is expected to reach USD 17.32 Billion by 2028 with a CAGR of 7.47% over the forecast period.
Growing geriatric population, rising prevalence of immunodeficiency diseases, increasing adoption of IVIG treatments and rising use of off-label indications are the key drivers of the Global Intravenous Immunoglobulin Market.
Intravenous Immunoglobulin (IVIg), a compound comprising of immune proteins (globulins) is administered into the bloodstream to treat patients with inefficient or damaged immune systems. IVIg provides the required antibodies to the human body to fight out the immune deficiency, and the ensuing infectious attacks. Immunoglobulin also referred as antibodies, are the glycoprotein molecules manufactured by the plasma or white blood cells. Immunoglobulin’s form a very critical line of defense of the immune system by specially recognizing and binding itself to particular antigens such as bacteria and viruses and aid in their destruction. In certain individuals, immunoglobulins have to be administered for the treatment and management of diseases such as primary immunodeficiency (PI). Intravenous immunoglobulins are the most popular form of immunoglobulin due to the no requirement for self-administration and the easy administration in hospital and clinic settings. Different classes of immunoglobulin such as IgA, IgG, and IgM are used for the treatment of various neurological and immunological diseases.
Global Intravenous Immunoglobulin market report is segmented on the basis of type, application, end-users, and region & country level. Based on type, global intravenous immunoglobulin market is classified into IgG, IgA, IgM, IgE, and IgD. Based on application global intravenous immunoglobulin market is classified into hypogammaglobulinemia, immunodeficiency diseases, congenital AIDS, chronic inflammatory demyelinating polyneuropathy, myasthenia gravis, multifocal motor neuropathy, ITP, Guillain-Barre syndrome, Kawasaki Diseases, and others. Based on end-user, the global intravenous immunoglobulin market is classified into hospitals, clinics, homecare, and others.
The regions covered in this intravenous immunoglobulin market report are North America, Europe, Asia-Pacific and the Rest of the World. On the basis of country level, the market of intravenous immunoglobulin is sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.
Global intravenous immunoglobulin market report covers prominent players like
The rising elderly population, increasing occurrence of immunodeficiency disorders, growing implementation of IVIG procedures, and increasing usage of off-label indications are some of the major factors driving the market growth. An increasing number of patients with immunodeficiency disease is the primary reason for the expansion of IVIG procedures. According to the World Health Organization (WHO), there are approximately 50 diverse Primary Immune Deficiency (PID) such as X-lined hypo-gamma-globulinemia, specific antibody deficiency, and others. Furthermore, according to the U.S. National Library of Medicine and National Institute of Health, around 6 million patients are suffering from Primary Immune Deficiency (PID) globally.
Rising occurrences of these immune diseases is expected to foster the demand for intravenous immunoglobulin treatments during the forecast period. However, stringent government regulations regarding the use of intravenous immunoglobulin products and the high risk of side effects associated with them are expected to hinder the growth of the market. Moreover, high adoption of intravenous immunoglobulins for the treatment of various diseases is expected to create lucrative opportunities in the near future.
North America is expected to dominate the global intravenous immunoglobulin market. Increasing healthcare expenditure, growing level of consciousness for the products involved in the treatment of immunodeficiency disorders, and rising inclination of clinicians towards immunodeficiency therapies are the key factors attributing towards the market growth. Additionally, growing occurrences of primary immunodeficiency (PID) are also expected to enhance the market growth in this region. According to American Autoimmune Related Disease Association Inc. (AARDA) 2012, approximately 50 million Americans were diagnosed to have autoimmune diseases and the number of people suffering this disease.
Asia Pacific is expected to show significant growth at a considerable CAGR over the forecast period owing to the increasing awareness and potential opportunities for adoption of immunoglobulin-based therapies for the treatment of primary immune deficiencies coupled with the growing geriatric population in this region.
|Historical data||2015 - 2020|
|Forecast Period||2021 - 2028|
|Market Size in 2021:||USD USD 10.46 Billion|
|Base year considered||2020|
|Forecast Period CAGR %:||
|Market Size Expected in 2028:||USD 17.32 Billion|
|Tables, Charts & Figures:||175|
|IVIG Manufacturers||Omrix Biopharmaceuticals Ltd., Hualan Biological Engineering Inc., Shanghai RAAS Blood Products Co. Ltd., Behring GmbH, Option Care Enterprises, Inc., BioScrip, Inc, ADMA Biologics, Inc., CSL Ltd., Others|
|Segments Covered||By Type, By Application, By End-Users|
|Regional Analysis||North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa|
The Middle East and Africa
We are always looking to hire talented individuals with equal and extraordinary proportions of industry expertise, problem solving ability and inclination interested? please email us firstname.lastname@example.orgJOIN US
BrandEssence® Market Research and Consulting Pvt ltd.
124, City Road, London EC1V 2NX
© Copyright 2023-24 BrandEssence® Market Research and Consulting Pvt ltd. All Rights Reserved | Designed by BrandEssence®